CTOs on the Move

APT Pharmaceuticals

www.aptbio.com

 
APT Pharmaceuticals, Inc is a Burlingame, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.aptbio.com
  • 700 Airport Blvd Ste 350
    Burlingame, CA USA 94010
  • Phone: 650.931.1666

Executives

Name Title Contact Details

Similar Companies

OnKure Therapeutics

OnKure, Inc. is a biopharmaceutical company focused on the discovery and development of targeted small molecule drugs to improve the outcomes of patients afflicted with cancer. OnKure`s drug candidates aim to treat patients by targeting malignant cells directly, by working in combination with other small molecule therapies and by priming the tumor microenvironment such that checkpoint inhibition is optimized.

Allied Research International

Allied Research International is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Terns Pharmaceuticals

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. Terns` programs are based on clinically validated and complementary mechanisms of action to address the multiple hepatic disease processes of NASH in order to drive meaningful clinical benefits for patients. Terns` investors include OrbiMed, Vivo Capital, Lilly Asia Ventures, and Decheng Capital.

Merck Frosst Canada

Merck Frosst Canada is a Kirkland, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cognito Therapeutics

Cognito Therapeutics is a pioneer in non-invasive neuromodulation to treat neurodegenerative diseases and improve human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer`s disease. Cognito has received FDA Breakthrough Device Designation for the treatment of Alzheimer`s disease and expects to start pivotal studies in 2022. The company`s technology was based on pioneering optogenetics research by scientific co-founders Professors Li-Huei Tsai and Ed Boyden at MIT.